Almorexant (INN; development code ACT-078573) is an orexin antagonist, functioning as a competitive receptor antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011 due to undisclosed issues pertaining to almorexant's safety profile.

Property Value
dbo:abstract
  • Almorexant (INN; development code ACT-078573) is an orexin antagonist, functioning as a competitive receptor antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011 due to undisclosed issues pertaining to almorexant's safety profile. (en)
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2019-09-24 15:14:55Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 19451365 (xsd:integer)
dbo:wikiPageLength
  • 5197 (xsd:integer)
dbo:wikiPageModified
  • 2019-09-24 15:08:26Z (xsd:date)
dbo:wikiPageOutDegree
  • 28 (xsd:integer)
dbo:wikiPageRevisionID
  • 917593673 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Almorexant (INN; development code ACT-078573) is an orexin antagonist, functioning as a competitive receptor antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011 due to undisclosed issues pertaining to almorexant's safety profile. (en)
rdfs:label
  • Almorexant (en)
owl:sameAs
foaf:depiction
foaf:homepage
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is foaf:primaryTopic of